Category

Cohort News

Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer

//
Categories
(690,000 patients annually are diagnosed with metastatic lytic bone lesions with only non-curative, palliative therapies available) ZetaMet™ (Zeta-BC-003) is a first-of-its kind molecular pathway designed to resolve metastatic cancer lesions, inhibit pain, and regenerate bone Phase 2a study examines the...
Read More →